Evidence map›Paper›PMID 41070604›Full record

ArticleFuture medicinal chemistry2025

New thiosemicarbazones: synthesis, structural characterization, in vitro, and in silico evaluation of antiproliferative effects.

Hanife Ardahanli, Yavuz Derіn, Raşit Fikret Yilmaz, Haşim Gül, Mustafa Sertçelіk, Ahmet Tutar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hanife ArdahanliFaculty of Medicine, Department of Basic Medical Sciences, Division of Medical Microbiology, Kafkas University, Kars, Turkey.
Yavuz DerіnDepartment of Chemistry, Faculty of Science, Sakarya University, Sakarya, Turkey.
Raşit Fikret YilmazTurkish Naval Academy, Department of Fundamental Sciences, National Defence University, İstanbul, Turkey.ORCID 0000-0001-5505-1727
Haşim GülDepartment of Chemistry, Faculty of Science, Sakarya University, Sakarya, Turkey.
Mustafa SertçelіkFaculty of Engineering and Architecture, Department of Chemical Engineering, Kafkas University, Kars, Turkey.
Ahmet TutarDepartment of Chemistry, Faculty of Science, Sakarya University, Sakarya, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo design, synthesize, and characterize MATERIALS &

methodsCompounds were obtained by condensations of substituted fluorobenzaldehydes with

resultsAll compounds decreased viability in a concentration-dependent manner. In MDA-MB-231, Compounds I, II, and IV showed significant effects (ANOVA

conclusionsThe 4-bromophenyl thiosemicarbazone/Schiff-base scaffold exhibits measurable antiproliferative activity with substitution-dependent trends supported by docking. These findings warrant structure optimization to enhance potency and selectivity and motivate follow-up mechanistic assays. (Not a clinical trial; CONSORT not applicable.).

Indexed as

Antineoplastic AgentsThiosemicarbazonesCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsThiosemicarbazonesantiproliferative activitycytotoxicityDLD-1MDA-MB-231MMP-2 inhibitorsmolecular dockingstructure elucidationThiosemicarbazone derivatives

Identifiers

PMID41070604
PMCPMC12582111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.